Revvity shares rise after Q1 beat as analysts focus on China divestiture, AI adoption

Revvity (RVTY) shares traded at $98.96 on May 15, 2026, up from $86.51 before its first-quarter earnings report, after the company posted stronger-than-expected organic growth and margins. Management said performance was driven by execution in its Life Sciences and Diagnostics segments, with gains in reagents, instruments and reproductive health. CEO Prahlad Singh said better-than-anticipated revenue and margin results reflected resilience among pharma, biotech and academic customers. Demand for high-content screening and recent software launches also supported results. Key investor questions following the call include the timing and financial impact of the China immunodiagnostics divestiture, adoption of new AI-driven software and instrument launches, and whether demand recovery among pharma, biotech and academic customers can continue. Investors are also monitoring operational efficiency programs and capital deployment updates.